» Articles » PMID: 36699018

Relationship Between Body Composition, Insulin Resistance, and Hormonal Profiles in Women with Polycystic Ovary Syndrome

Overview
Specialty Endocrinology
Date 2023 Jan 26
PMID 36699018
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate how body fat influences glucose metabolism and hormone profiles in women with polycystic ovary syndrome (PCOS), compared to women without PCOS.

Methods: We conducted a cross-sectional study of 166 women with PCOS and 139 age-matched control women at Peking University Third Hospital (Beijing, China) from March 2016 to December 2021. All participants underwent bioimpedance rate assessment of clinical, anthropometric, hormonal, and metabolic features. In particular, body composition parameters were assessed, based on the methods used in a previous study. Homeostasis model assessment-insulin resistance (HOMA-IR) and other indices calculated from fasting glucose and insulin were used to measure insulin resistance. The hormonal profiles [follicle-stimulating hormone (FSH), luteinizing hormone (LH), estrogen (E2), prolactin (PRL), total testosterone (T), and androstenedione (A2)] were assessed by using biochemical methods. Two subgroup analyses were conducted according to waist-to-hip ratio (WHR; < 0.85, non-central obesity and ≥ 0.85, central obesity) and body fat percentage (BFP; < 35% for lean and ≥35% for obesity). The indices above were analyzed using a two-sided t-test or Wilcoxon rank sum test. Linear regression was used to investigate the effects of body composition on metabolism and sex hormones in the PCOS and control groups.

Results: Compared to women without PCOS, women with PCOS and central obesity (=0.021), PCOS and noncentral obesity (<0.001), PCOS and high BFP (<0.001), and PCOS and low BFP (<0.001) had more severe glucose metabolism evaluated with HOMA-IR. Women with PCOS experienced greater insulin sensitivity impairment than did the normal population for every equal increase in BFP. LH, LH/FSH, total testosterone, and androstenedione were significantly higher in patients with PCOS than in healthy controls, regardless of WHR and BFP stratification. However, negative correlations existed between body fat indices (i.e., BFP and body mass index) and hormone indices (i.e., LH and androstenedione) in the PCOS group, but were absent in the control group.

Conclusions: Obese and non-obese women with PCOS have more severe insulin resistance and sex-hormone disorders than women without PCOS. The effect of body fat on sex-hormone disorders is only exist in women with PCOS. These findings suggested that PCOS clinical guidelines should be more specific to body fat.

Clinical Trial Registration: https://clinicaltrials.gov/, Registration No. NCT04264832.

Citing Articles

The waist-to-height ratio is a good predictor for insulin resistance in women with polycystic ovary syndrome.

Zhu M, Wang K, Feng J, Liu Y, Guan M, Wang Y Front Endocrinol (Lausanne). 2024; 15:1502321.

PMID: 39717101 PMC: 11664359. DOI: 10.3389/fendo.2024.1502321.


Obesity is associated with SHBG levels rather than blood lipid profiles in PCOS patients with insulin resistance.

Zhang H, Qiu W, Zhou P, Shi L, Chen Z, Yang Y BMC Endocr Disord. 2024; 24(1):254.

PMID: 39587600 PMC: 11587586. DOI: 10.1186/s12902-024-01789-w.


The impact of vitamin D3 administration and of high fat diet on oxidative stress and inflammation in experimentally induced polycystic ovary syndrome.

Vulcan T, Suciu T, Lenghel L, Toma V, Decea N, Moldovan R Med Pharm Rep. 2024; 97(4):516-527.

PMID: 39502756 PMC: 11534383. DOI: 10.15386/mpr-2798.


Shared diagnostic genes and potential mechanisms between polycystic ovary syndrome and recurrent miscarriage revealed by integrated transcriptomics analysis and machine learning.

He J, Liu A, Shen H, Jiang Y, Gao M, Yu L Front Endocrinol (Lausanne). 2024; 15:1335106.

PMID: 39398336 PMC: 11466764. DOI: 10.3389/fendo.2024.1335106.


Hyperandrogenism and anthropometric parameters in women with polycystic ovary syndrome.

Mansour A, Noori M, Hakemi M, Haghgooyan Z, Mohajeri-Tehrani M, Mirahmad M BMC Endocr Disord. 2024; 24(1):201.

PMID: 39333998 PMC: 11438141. DOI: 10.1186/s12902-024-01733-y.


References
1.
Panidis D, Koliakos G, Kourtis A, Farmakiotis D, Mouslech T, Rousso D . Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril. 2004; 81(2):361-6. DOI: 10.1016/j.fertnstert.2003.06.021. View

2.
Escobar-Morreale H . Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018; 14(5):270-284. DOI: 10.1038/nrendo.2018.24. View

3.
Kaluzna M, Czlapka-Matyasik M, Bykowska-Derda A, Moczko J, Ruchala M, Ziemnicka K . Indirect Predictors of Visceral Adipose Tissue in Women with Polycystic Ovary Syndrome: A Comparison of Methods. Nutrients. 2021; 13(8). PMC: 8401513. DOI: 10.3390/nu13082494. View

4.
Deswal R, Narwal V, Dang A, Pundir C . The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. J Hum Reprod Sci. 2021; 13(4):261-271. PMC: 7879843. DOI: 10.4103/jhrs.JHRS_95_18. View

5.
Glueck C, Goldenberg N . Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism. 2018; 92:108-120. DOI: 10.1016/j.metabol.2018.11.002. View